1st Quarter - Report — PARENT PROJECT MUSCULAR DYSTROPHY for PARENT PROJECT MUSCULAR DYSTROPHY (2016)

Firm

PARENT PROJECT MUSCULAR DYSTROPHY

Client

PARENT PROJECT MUSCULAR DYSTROPHY

Income

—

Expenses

$80,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

21st Century Cures/Biomedical Innovations; Patient-Focused Impact Assessment Act; Congressionally Directed Medical Research Program; FDASIA/FDA reviews; Patient-Focused Drug Development in PDUFA VI

Lobbyist	Covered position, as disclosed
ANNIE KENNEDY	—

Contacted: Centers For Disease Control & Prevention (CDC); Food & Drug Administration (FDA); SENATE; Natl Institutes of Health (NIH); HOUSE OF REPRESENTATIVES; Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS)

Budget/Appropriations BUD

Fiscal year 2017 appropriations

Lobbyist	Covered position, as disclosed
ANNIE KENNEDY	—

Contacted: Food & Drug Administration (FDA); SENATE; Centers For Disease Control & Prevention (CDC); Natl Institutes of Health (NIH); Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Science/Technology SCI

Advancing Target Therapies for Rare Diseases Act

Lobbyist	Covered position, as disclosed
ANNIE KENNEDY	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Natl Institutes of Health (NIH); Centers For Disease Control & Prevention (CDC); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.